Secukinumab 300 mg viable first-line biologic in patients with psoriatic arthritis

Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.
“Secukinumab (SEC), a human monoclonal antibody that selectively targets interleukin 17A, has proven to be efficacious and safe for the treatment of PsA,” Tien Nguyen, MD, of First OC Dermatology, in Irvine, California, and co-authors wrote in The Journal of Rheumatology. “Responses to therapy include resolution of enthesitis and dactylitis; improvement in skin and nail PsO and in axial

Secukinumab 300 mg is a safe and effective first-line biologic for patients with psoriatic arthritis, according to data from a biologic-naïve population based in the United States.
“Secukinumab (SEC), a human monoclonal antibody that selectively targets interleukin 17A, has proven to be efficacious and safe for the treatment of PsA,” Tien Nguyen, MD, of First OC Dermatology, in Irvine, California, and co-authors wrote in The Journal of Rheumatology. “Responses to therapy include resolution of enthesitis and dactylitis; improvement in skin and nail PsO and in axial